Future treatment perspectives

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Vella, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiretroviral; HIV 1 Infection; Resistance testing; Toxicity

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG SAFETY; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONG TERM CARE; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 0141793111     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00015     Document Type: Conference Paper

References (31)

1. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998;280:1866-1867.
2. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Henry J. Kaiser Family Foundation, 13 August 2001.
3. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-391.
4. + T-cell count gains in patients with 4 years of suppressed viral load on HAART [abstract 480]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
5. + cell counts [abstract 13]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
6. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
7. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-1122.
8. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30(suppl 2):S135-S142.
9. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
10. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139.
11. Walli RK, Herfort O, Michl GM, et al. Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors [abstract 777]. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.
12. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. JAIDS 2001;27:229-236.
13. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-810.
14. Montaner JSG, for the CNA30017 Study Team. A novel use of abacavir to simplify therapy and reduce toxicity in PI experienced patients successfully treated with HAART: 48-week results (CNA30017) [abstract 477]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000.
15. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-1822.
16. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
17. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-510.
18. Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - a prospective, randomized, multicenter, open-label study (DMP 049) [abstract 20]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
19. Bonnet EPP, Yovanovitch JD, Mularczyk MB, et al. Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidaemia in HIV-infected patients [abstract 1538]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada, 17-20 September 2000.
20. Miller V. HIV drug resistance: overview of clinical data. J HIV Ther 2001;6:68-71.
21. Miller V. Interpretation of resistance assay results. Antivir Ther 2001;6(suppl 2):1-9.
22. Abbott Laboratories. Kaletra® (lopinavir/ritonavir) Product Monograph, North Chicago, IL, U.S.A., April 2001.
23. Sankatsing S, Weverling G, van't Klooster G, et al. TMC125 Monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen [abstract 5]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
24. Gazzard B, Pozniak A, Arasteh K, et al. TMC125, A next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance [abstract 4]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
25. Schwartz R, Kazanjian P, Slater L, et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2) [abstract 562]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
26. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
27. Altfeld M, Rosenberg ES, Eldridge RL, et al. Increase in breadth and frequency of CTL responses after structured therapy interruptions in individuals treated with HAART during acute HIV-1 infection [abstract 357]. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, U.S.A., 2000.
28. García F, Plana M, Ortiz GM, et al. Outcome after 1 year of HAART, 3 cycles of STI and 12 months off therapy vs natural evolution without ART in early chronic HIV-1 infection (CHI). A case-control study [abstract 289]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
29. Hermans P, Kabeya K, Van Wanzeele F, et al. Successful interruption of antiretroviral therapy (ARVT) in patients with primary HIV infection (PHI) [abstract 290]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
30. Markowitz M, Jin X, Ramratnam B, et al. Prolonged HAART initiated within 120 days of primary HIV-1 infection does not result in sustained control of HIV-1 after cessation of therapy [abstract 288]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, U.S.A., 4-8 February 2001.
31. Hirschel B, Fagard C, Oxenius A, et al., for the Swiss HIV Cohort Study. SSITT: A prospective trial of treatment interruptions in HIV infection [abstract 528]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.